

C & M INTERNATIONAL, LTD.

1001 PENNSYLVANIA AVENUE, N.W.  
SUITE 1275  
WASHINGTON, D.C. 20004-2595  
(202) 624-2895  
FACSIMILE: (202) 628-5116

SECRETARY OF THE SENATE

00 APR 14 PM 2:34

H.D.

DORAL S. COOPER  
PRESIDENT

April 10, 2000

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510


To Whom It May Concern:

Please find enclosed the only copy I have left of the original Novartis Lobbying Report, that was sent to your office on February 10, 2000. I believe since all our reports were sent at once, and you have seemed to have received the rest, that Novartis was lost in the mail.

So, in response to a letter I received from the Office of the Clerk I am forwarding the Office of Public Records a copy.

If you have any questions, please do not hesitate to call me at (202) 624-2501.

Sincerely,

  
Alexandra Ramos  
Office Manager  
C&M International

Clerk of the House of Representatives  
 Legislative Resource Center  
 B-106 Cannon Building  
 Washington, DC 20515

Secretary of the Senate  
 Office of Public Records  
 232 Hart Building  
 Washington, DC 20510

SECRETARY OF THE SENATE  
 00 APR 14 PM 2:34  
 H.D.

**LOBBYING REPORT**  
 Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Crowell & Moring International, Ltd.			
2. Address <input type="checkbox"/> Check if different than previously reported 1001 PENNSYLVANIA AVENUE, NW; WASHINGTON, DC 20004			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country): _____			
4. Contact Name Doral S. Cooper	Telephone 202-624-2895	E-mail (optional)	5. Senate ID # 11388-75
7. Client Name <input type="checkbox"/> Self Novartis Corporation			6. House ID # 31881004

**TYPE OF REPORT** 8. Year 99 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_ 11. No Lobbying Activity

**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input checked="" type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____  <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____  <small>Expenses (nearest \$20,000)</small></p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>
---	---

Signature: *Doral S. Cooper*

Printed Name and Title: Doral S. Cooper, President

LD-2 (REV. 6/98) PAGE 1 of \_\_\_\_\_

Registrant Name Crowell & Moring Int'l Client Name Novartis Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LT&D (one per page)

16. Specific lobbying issues


No specific issues in current reporting period

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Doral S. Cooper		<input type="checkbox"/>
Melissa Coyle		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date 2/10/2000  
Printed Name and Title Doral S. Cooper, President

Office of the Clerk  
**U.S. House of Representatives**  
Washington D.C. 20515-0601

MR. DORAL S. COOPER  
CROWELL & MORING INTERNATIONAL, LTD  
1001 PENNSYLVANIA AVENUE, NW, #1275  
WASHINGTON, DC 20004

April 04, 2000

Re: NOVARTIS CORPORATION - ID: 31881004

**FIRST NOTICE OF NON-RECEIPT**

The Lobbying Disclosure Act of 1995, 2 USC 1601-1612, empowers the Clerk of the House of Representatives to verify and inquire to ensure the timeliness of registrations and reports.

A review of Reports on file with the Legislative Resource Center indicates that you have neither terminated your registration nor submitted a report for the period July 1, 1999 to December 31, 1999, which report was due by FEBRUARY 14, 2000.

Please provide us (within 30 days) with an appropriate filing and a written explanation of any delinquency.

For further information, please contact the Legislative Resource Center, B106 Cannon House Office Building, Washington, DC 20515-6612, (202) 226-5200.